NewYork-Presbyterian is home to the Herbert Irving Comprehensive Cancer Center of NewYork-Presbyterian/Columbia University Irving Medical Center and the Weill Cornell Medicine Meyer Cancer Center in partnership with NewYork-Presbyterian, both National Cancer Institute-designated comprehensive cancer centers. Thanks to this, it places among a small number of New York state health systems to hold that dual designation. Precision medicine is central to its approach: the Columbia Precision Medicine Initiative and the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell analyze individual tumor biology to guide treatment selection across cancer types. The system’s investigators helped pioneer immunotherapies now used to treat melanoma, lymphoma, kidney, breast, bladder and prostate cancers, head and neck cancers, some colorectal cancers, and liver cancer, backed by an active clinical trials program spanning nearly every disease site. Surgeons across specialties including urologic, gynecologic, thoracic and colorectal oncology perform minimally invasive and robotic procedures, and the breast cancer program holds accreditation from the American College of Surgeons’ national accreditation program for breast centers. The blood cancers program performs hundreds of stem cell transplants annually and has particular expertise in transplants from mismatched donors, while its center for liver disease and transplantation treats benign and malignant liver tumors with options including transplantation and minimally invasive resection. Pediatric cancer patients are treated at the Children’s Hospital of New York and NewYork-Presbyterian Morgan Stanley Children’s Hospital, where genetic tumor analysis and access to phase 1 clinical trials draw families from around the world.
